Premium
Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment
Author(s) -
Nagai Tadashi,
Karakawa Masaru,
Komine Mayumi,
Muroi Kazuo,
Ohtsuki Mamitaro,
Ozawa Keiya
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12153
Subject(s) - nilotinib , medicine , psoriasis , dasatinib , imatinib , dermatology , tyrosine kinase inhibitor , chronic myelogenous leukemia , pharmacology , leukemia , myeloid leukemia , cancer
The tyrosine kinase inhibitor ( TKI ) imatinib has been shown to promote psoriasis in some patients with chronic myelogenous leukaemia ( CML ), but it remained unclear whether second‐generation TKI s such as nilotinib and dasatinib had a similar potential. Here, we present a patient in whom psoriatic erythema appeared at 26 months after initiation of nilotinib treatment. Topical ointments of activated vitamin D 3 derivative and corticosteroid were applied; whereupon, the erythema gradually improved. During the clinical course, nilotinib administration continued without reduction in its dose. This is the first report of psoriasis that developed during nilotinib treatment. We also discuss the mechanisms of nilotinib‐mediated progression of psoriasis.